Navigation Links
Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/17/2007

ber 20 at 10:00 AM, Room E253D:

-- Poster F1-2116, titled "In vitro Activity of REP8839 against

Pasteurella species and Other Fastidious Bacteria Isolated from

Infected Animal Bites in Humans."

About Clostridium difficile

C. difficile is a Gram-positive anaerobic bacterium that causes C. difficile-associated disease (CDAD). CDAD is on the rise worldwide, both in terms of number of cases and severity of the disease. Most cases of CDAD occur in a hospital setting due to increased use of antibiotics and other chemotherapeutics that disrupt normal intestinal flora, an ageing population, and difficulty of eradicating C. difficile spores. However, more recently, CDAD has been acquired in the community setting where several outbreaks with increased mortality have occurred. The emergence of an epidemic, hypervirulent C. difficile strain (BI/NAP1, 027) that produces high levels of toxins poses a real threat to public health and demands improved infection control as well as novel treatment options.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product, faropenem medoxomil, is a novel oral, community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's second drug candidate, REP8839, is a topical anti-infective product candidate in development for the treatment of skin and wound infections, including methicillin-resistant S. aureus (MRSA) infections. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and related diseases. In preclinical studies, REP3123 has been show to inhibit growth, toxin production and spore-forming in C. difficile bacteria. Replidyne is also pursuing the development of other novel anti-infective programs bas
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
2. $30 M Aid in the pipeline by WB for bird flu in Turkey
3. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
4. Battery power from viruses in the pipeline
5. Effective Vaccine for Leishmaniasis in the Pipeline
6. Home Test Kit for AIDS in the Pipeline
7. Sensing Devices to Measure Sleep In the Pipeline
8. Blood Fluke Vaccine in the Pipeline
9. Chlamydial Vaccine for Humans in the Pipeline
10. New Treatment Option in the Pipeline for Those Suffering From Lung Cancers
11. Treatment of Endometriosis in the Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 2Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 3Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 4Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 5Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 6Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 7Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 8Health News:Bradmer announces 2008 fourth quarter and fiscal year operational and financial results 9Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 2Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 3Health News:Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer 4Health News:Virus evolution topic of Darwin talk at UH April 2 2Health News:Study Casts Doubt on Influential Hospital Safety Survey 2Health News:Study Casts Doubt on Influential Hospital Safety Survey 3Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 2Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 3Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 4Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 5Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 6Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 7Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 8Health News:Novavax Reports Fourth Quarter and 2008 Year-End Financial Results 9Health News:National Council on Disability Calls for New Federal Approach to Disability Policy 2
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Donor Stem Cell Transplant Best For Acute Myeloid Leukemia 48368 1Donor Stem Cell Transplant Best For Acute Myeloid Leukemia 48368 2Donor Stem Cell Transplant Best For Acute Myeloid Leukemia 48368 3Health care issues lead latest Arizona State University Southwest Poll 48364 1Health care issues lead latest Arizona State University Southwest Poll 48364 2Health care issues lead latest Arizona State University Southwest Poll 48364 3Health care issues lead latest Arizona State University Southwest Poll 48364 4Story tips from the Department of Energys Oak Ridge National Laboratory June 2009 8774 1Story tips from the Department of Energys Oak Ridge National Laboratory June 2009 8774 2Story tips from the Department of Energys Oak Ridge National Laboratory June 2009 8774 3